This project, funded by the National Institutes of Health, is being conducted to learn how structures of the middle-ear and inner ear are affected by age and hearing ability, and to provide a scientific basis for diagnosis and rehabilitation of hearing loss. Volunteers who meet the eligibility requirements may enroll in this study, which will include measurements of hearing using several procedures. Participants 18 years of age and older with normal hearing or hearing loss are currently being recruited. One or two visits of 1.5 to 2 hours are required and scheduling is flexible. Compensation for time will be provided and parking validated.
The purpose of this study is to find out whether a treatment that raises urate (also known as uric acid) levels can slow the rate of worsening in Parkinson's disease (PD). There is evidence that increased urate levels can predict both a lower risk of developing PD and a slower rate of its worsening over time. In this study, we will elevate blood urate levels with a supplement called Inosine. This research study will compare Inosine to a placebo. During this study you may get a placebo or Inosine. Study participation will consist of screening visits which include physical exam, lab work, questionnaires, and an additional scan. If you are eligible for the study, you will participate in approximately 10 study visits over approximately 2 years.
This is a study of brain aging and Mild Cognitive Impairment (MCI). In this study, we use non-invasive brain MRI techniques and tests of memory and other thinking skills to improve the detection of brain diseases of aging at the very earliest stages. A fasting blood draw will also be performed to help clarify the contribution of blood sugar and cholesterol to brain aging. We are primarily recruiting 80 individuals ages 65-85 who have been diagnosed with Mild Cognitive Impairment (MCI) by their healthcare provider. We are also recruiting individuals ages 65-85 who are cognitively healthy and do not have any significant or unstable medical conditions. This study is sponsored by the NIH and is conducted at MUSC.
If you are interested in this study, please contact us by phone or through: http://bit.ly/MIND-study
South Carolina Coalition for Care of Serious Illness (SCC CSI) sponsors development of Physician Orders for Scope of Treatment (POST) in South Carolina. The SC POST follows the national POLST (www. polst.org) paradigm creating an advance treatment planning physician order that migrates as valid across institutional boundaries: from physician office, to home/nursing home/hospice to EMS to hospital emergency/inpatient services. The POST form encourages a conversation between a physician and the patient regarding treatment options available to seriously ill patients for whom death within a year would not be a surprise. These choices primarily include whether to attempt cardiopulmonary resuscitation in the event of cardiac or pulmonary arrest or not (a "DNR" or "Allow Natural Death" order) and whether during acute illness to provide full treatment including endotracheal intubation and intensive care, supportive treatment such as noninvasive ventilation and no intensive care, or comfort care only. The Charleston and Greenville areas will pilot POST. Investigators by area will survey providers completing POST documents for patients or treating patients with POST about the utility of this form and how use of the form affected their patient's treatment. A chart reviews of patients presenting with a POST form to a hospital emergency or inpatient unit will address whether providers respected patient treatment choices. SCC CSI plans to publish the results of the pilot in appropriate journals and present the results at medical meetings and to interested persons. The results of the study may provide the supporting documentation for subsequent legislation supporting POST. POST represents a coordinated statement of a seriously ill patient's treatment choices to be honored across multiple treatment settings.
This study is designed to examine the effects and safety of citalopram in patients with Alzheimer's disease experiencing agitation or emotional disturbance. This study is 9 weeks long. In order to participate in this study, you must be at least 45 years old, have Alzheimer's disease and experience agitation. Participants cannot have depression. Participants may stay on approved memory medications for Alzheimer's disease.
This project, funded by the National Institutes of Health, is being conducted to determine the effects of aging on hearing, understanding speech, and brain functions. This study will provide a scientific basis for diagnosis, rehabilitation and prevention of hearing loss due to aging. Volunteers who meet the eligibility requirements may enroll in this study, which will include measurements of hearing, making listening judgments of sounds, behavioral tasks, questionnaires, and MRI scanning of the brain. Participants 60 years of age and older with normal hearing or hearing loss are currently being recruited. Three visits of 2-3 hours each are required and scheduling is flexible.